Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 25;40(6):1242-1248.
doi: 10.7507/1001-5515.202309041.

[Research progress of biomarkers of hepatitis B virus and clinical significance]

[Article in Chinese]
Xin Wang  1   2 , Xiaoqiong Tang  1   2 , Ning Han  1   2 , Hong Tang  1   2
Affiliations
Review

[Research progress of biomarkers of hepatitis B virus and clinical significance]

[Article in Chinese]
Xin Wang et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. .

Abstract
in English, Chinese

The infection of Hepatitis B virus (HBV) can result in severe consequences, including chronic hepatitis, liver fibrosis, cirrhosis, and even liver cancer. Effective antiviral treatment has the potential to slow down the progression of the disease. HBV serum biomarkers play a crucial role in the dynamic management of chronic hepatitis B (CHB) patients. However, the conventional hepatitis B virus markers, such as hepatitis B serologic testing and HBV DNA, are insufficient to meet the clinical requirements. This review provided a comprehensive overview of the current research on the quantification of HBsAg and anti-HBc, HBV RNA and HBV core-associated antigen, which summarized the crucial role these markers play in the administration of antiviral medications, predicting the efficacy of treatment and anticipating the likelihood of virologic rebound following drug cessation, as well as assessing disease progression in CHB patients.

乙型肝炎病毒（HBV）感染可导致慢性肝炎、肝纤维化甚至肝硬化或肝癌等严重后果，有效的抗病毒治疗可以减缓疾病进展。乙肝病毒生物标志物在慢性乙型肝炎（CHB）患者全程动态化管理中具有重要作用，而经典乙肝病毒标志物（如乙肝两对半、HBV DNA）尚不能完全满足临床需求。本文综述了HBsAg定量、抗-HBc定量、HBV RNA和HBV核心相关抗原等HBV标志物的最新研究，总结了这些标志物在CHB患者抗病毒治疗中的使用、疗效预测和停药后复发风险预测，以及疾病进展风险评估等方面的作用。.

Keywords: Biomarkers; HBV RNA; HBcrAg; Hepatitis B virus.

PubMed Disclaimer

Conflict of interest statement

利益冲突声明：本文全体作者均声明不存在利益冲突。

Similar articles

See all similar articles

References

    1. Global HIV, Hepatitis and Sexually Transmitted Infections Programmes. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact. Geneva: WHO, 2022.

    1. Yoo S, Kim J Y, Lim Y S, et al Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol. 2022;77(4):939–946. doi: 10.1016/j.jhep.2022.05.014. - DOI - PubMed
    1. Terrault N A, Lok A S, Wahed A S, et al Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B. Am J Gastroenterol. 2023;118(7):1214–1225. doi: 10.14309/ajg.0000000000002125. - DOI - PMC - PubMed
    1. Li M, Zhang L, Lu Y, et al Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferonα-2a. Virol Sin. 2021;36(2):311–320. doi: 10.1007/s12250-020-00290-7. - DOI - PMC - PubMed
    1. Brakenhoff S M, De Man R A, Boonstra A, et al Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther. 2021;53(2):314–320. doi: 10.1111/apt.16172. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources